Codacons

Codagenix is a clinical-stage synthetic biology company that uses its proprietary SAVE (Synthetic Attenuation of Viral Expression) platform to develop a new generation of live-attenuated vaccines and viral therapeutics. By utilizing software-based codon deoptimization, the company can rapidly design and synthesize viral genomes that are identical to the wild-type virus at the protein level but contain hundreds of mutations that prevent efficient replication in human cells. Their lead program, CoviLiv, is a needle-free, intranasal COVID-19 vaccine candidate currently in late-stage clinical development. Beyond COVID-19, Codagenix is advancing a diverse pipeline targeting respiratory syncytial virus (RSV), influenza, and various oncology indications. The company's approach aims to provide the robust immunity of live-attenuated vaccines with an enhanced safety profile and rapid manufacturing scalability.